Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3995 add-on therapy in type 2 diabetic nephropathy with albuminuria
2012-002480-98Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing MT-3995 add-on with Placebo add-on (2 arms). Primary endpoint: Efficacy endpoint. Started Jul 2012; status: completed.
02
Drugs
apararenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002480-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002480-98.